BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

The focus on robotics and enabling technologies, exemplified by the Excelsius platform and the new ExcelsiusFlex for total knee arthroplasty, positions Globus Medical at the forefront of ...

After 30 years of surgeries, medications, and chronic pain, Sue Mundy is finally walking pain-free, and she credits a new ...

Cheatle recommended a surgery using a robot called the Globus with Excelsius 3D Imaging. It helps to locate problems with pinpoint accuracy. PMC was one of the first hospital systems in the ...

Globus Medical reported a big jump in the immediately preceding Q4:2024 quarter. Globus Medical, Inc. reported $598 million in sales and $97 million in operating profit, which as a percent of sales ...

TORONTO — With more Canadians opting to explore closer to home, Globus is making it easier than ever to experience the country in unforgettable ways. From rugged West Coast mountains to the ...

Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. As of December ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.